Gyre Therapeutics (NASDAQ:GYRE) Shares Down 12.5% – Time to Sell?

Gyre Therapeutics, Inc. (NASDAQ:GYRE) shares fell 12.5% on Monday . The stock traded as low as $8.11 and last traded at $7.97. 99,280 shares traded hands during mid-day trading, an increase of 17% from the average session volume of 84,647 shares. The stock had previously closed at $9.11.

Wall Street Analysts Forecast Growth

Separately, Noble Financial started coverage on Gyre Therapeutics in a report on Tuesday, March 11th. They issued an “outperform” rating on the stock.

Gyre Therapeutics Trading Down 15.4 %

The company has a market cap of $721.75 million, a PE ratio of 154.20 and a beta of 1.93. The business’s 50 day moving average is $11.16 and its two-hundred day moving average is $12.07.

Gyre Therapeutics (NASDAQ:GYRE) last announced its quarterly earnings results on Monday, March 17th. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.03). Gyre Therapeutics had a negative return on equity of 118.43% and a negative net margin of 84.57%. The company had revenue of $27.87 million during the quarter, compared to analysts’ expectations of $23.50 million.

Institutional Trading of Gyre Therapeutics

Several institutional investors have recently added to or reduced their stakes in GYRE. FMR LLC bought a new stake in shares of Gyre Therapeutics in the third quarter valued at about $47,000. Wells Fargo & Company MN boosted its position in Gyre Therapeutics by 29.4% during the 4th quarter. Wells Fargo & Company MN now owns 4,016 shares of the company’s stock valued at $49,000 after acquiring an additional 913 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of Gyre Therapeutics by 40.4% in the 4th quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock valued at $84,000 after acquiring an additional 1,996 shares during the period. Barclays PLC raised its position in shares of Gyre Therapeutics by 281.8% in the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after acquiring an additional 6,855 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in shares of Gyre Therapeutics by 11.1% during the 4th quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company’s stock worth $168,000 after purchasing an additional 1,389 shares during the last quarter. Institutional investors own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.